Drugs.com - New Drug Approvals

U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors

WHIPPANY, N.J.--(BUSINESS WIRE) April 10, 2025 --Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Vitrakvi® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and...

Apr 14, 2025 - 06:43
 0
U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors
WHIPPANY, N.J.--(BUSINESS WIRE) April 10, 2025 --Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Vitrakvi® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and...
Read More

Tags:

Previous Article

Zalando Acquires AR Firm DeepAR

Next Article

Mercedes-Benz priming 'Little G' as £70k entry G-Class due in 2027

Related Posts

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

Feb 17, 2025  0

Bavarian Nordic Receives U.S. FDA Approval of Jynneos Freeze-Dried Smallpox and Mpox Vaccine

Bavarian Nordic Receives U.S. FDA Approval of Jynneos F...

Apr 1, 2025  0

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

FDA Approves Journavx (suzetrigine), a First-in-Class T...

Feb 9, 2025  0